TrivarX

Commercialising Al-driven solutions to objectively screen for mental health conditions

Investor presentation – May 2024 (ASX: TRI)

This presentation has been authorised for release by the Board of TrivarX Limited

Forward looking statements



The purpose of the presentation is to provide an update of the business of TrivarX Limited (ASX: TRI). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by TrivarX Limited and should not be relied upon as an independent source of information. Please contact TrivarX Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of TrivarX Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons) makes any representation or warranty as to the accuracy, complete-ness or reliability of the information, or the likelihood of fulfilment of any forward-looking statement or any out-comes expressed or implied in any forward-looking statements.

Any forward-looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside TrivarX Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

Actual results could differ materially to the assumptions made and TrivarX Limited's current intentions, plans, expectations and beliefs about the future. You are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.

This presentation should not be relied on as a recommendation or forecast by TrivarX Limited. This presentation does not constitute investment advice or should be construed as either an offer to sell, or a solicitation of an offer, to buy or sell shares in any jurisdiction.

Corporate overview



Corporate snapshot	
ASX code:	TRI
Shares on issue:	~409.6m
Market capitalisation (at \$0.027 per share): (as at 21 May 2024)	~A\$12.3m
Options on issue:	~158.3m
Debt:	Nil
Board and management	
Non-Executive Chairman	Mr David Trimboli
Chief Operating Officer	Mr Kai Sun
Non-Executive Director	Dr Thomas Young
Non-Executive Director	Mr Chris Ntoumenopoulos
Chief Medical Officer	Dr Archie Defillo
Head of Artificial Intelligence	Mr Massimiliano Grassi

Share price and volume** (May 2023– May 2024)

Top 20:



41.52%

Company overview



A US-based company pioneering the use of AI to aid in the early detection of mental health conditions



MEB-001 utilises biometric Data, EEG (Brain), ECG (Heart Rate) and HRV recordings collected during in-clinic sleep studies to screen for current Major Depressive Episode (cMDE)

Extensive Phase 2 Sleep Analysis of Depressive Burden Study is ongoing across 15 US-based sleep centres. In an interim analysis cMDE reported sensitivity of 86% and specificity of 75%

Defined pathway to US FDA regulatory approval via De Novo submission – Company has held multiple pre-submission meetings with the US FDA and gained positive feedback to date

Through its clinical trials, TrivarX has now built the world's largest database of sleep study data labelled with patient's mental health status

The US mental health epidemic

TrivarX

Exploring the robust relationship between sleep and mental health in the US



1 in 5 American adults (~57m people) experience a mental illness



1 in 25 US adults live with a serious mental health condition including major depression, bipolar and schizophrenia

Nearly 50% of serious mental health disorders are untreated

Mental health misdiagnosis is rife – Social anxiety: 97.8%, Bipolar: 92.7%, Panic disorder: 85.5%



Concurrently, data shows 75% of people with diagnosed depression also suffer from disrupted sleep patterns



A scientifically backed approach



Underpinned by leading management, extensive experience and industry validation

Extensive industry validation:

- Since the early 2000s, TRI's dedicated scientific personnel have built evidence to support that EEG, EKG and HRV data collected during sleep can be used to assist with the diagnosis of mental health conditions via AI and machine learning
- 13 peer reviewed publications and top congress scientific presentations
- Three clinical trials completed and a well progressed Phase 2 clinical trial for current Major Depressive Episode (cMDE) expected to complete mid CY2024
- TRI boasts data from over 880 subjects including 7,000 hours of sleep recording which includes concurrent mental health evaluation

Leading Scientific expertise:

Archie Defillo M.D. – Chief Medical Officer

- 25 years clinical experience with neurological diseases and a trained neurosurgeon
- 70+ publications on topics predominantly based on heart rate studies
- Dedicated to advancing TRI's knowledge of heart rate variability and autonomic modulation

Massimilano Grassi PhD – Head of AI

- 15 years experience as a data scientist in mental health field with an extensive background in psychology
- Ph. D in Supervised Machine Learning for Clinical Psychiatry
- Focused on the development of machine learning algorithms using sleep as the window into mental health.

Product overview



Interrelated product suite with significant commercialisation and scale up potential



Stager

- AI-based software that provides researchers with unique HR and HRV metrics combined with hypnodensity graphs from sleep study data
- Insights on the 4 key sleep stages in 30 minutes Industry standard currently ~2 hours
- Provides unique data beyond current sleep staging tools in the market
 - Data capture further informs MEB-001 and accelerates the development of additional mental health-sleep algorithms

MEB-001

- An innovative machine learning and AI-backed algorithm to screen sleep study patients for cMDE
- Uses Biometric Data, EEG (Brain), ECG (Heart Rate) and HRV recordings collected during-in-clinic sleep studies
- Identifies a patient with cMDE with 86% sensitivity and 75% specificity
- Defined route to market via FDA's De Novo pathway

Stager – Uptake and ongoing commercialisation

TrivarX

Stager solution unlocks potential to establish a strong in-market presence while strengthening MEB-001



MEB-001 – redefining sleep and depression



MEB-001 has the potential to become the standard depression symptom screening tool within US Health Systems

aid in	Clinical	Regulatory		
with a	Early Clinical			
	Feasibility Phase 1	FDA pre submission meeting 1		
ed to	Feasibility Phase 2 <i>(underway)</i>	FDA pre submission meeting 2 (scheduled in Q1 FY25)		
US or	Pivotal	FDA De Novo submission		
		FDA Clearance		

TrivarX's proprietary algorithm is being developed as a tool to be used to screen and aid ir the diagnosis of cMDE

Current algorithm performance demonstrates an 86% sensitivity and 75% specificity with a 44% PPV and 95% NPV

Algorithm only requires data collected from a standard sleep study:

- ~60-70% of patients with Sleep Apnea (SA) have depressive symptoms
- Circa 39m US adults suffer from Obstructive Sleep Apnea

- Ph

Phase 2 SAMDE trial well progressed and US FDA approval process being advanced to unlock value and commercialisation potential

 There is no standard depression symptom screening carried out in sleep centres in the US or globally – highlighting current market opportunity

*Screening for Depression in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force. Prepared by: Kaiser Permanente Research Affiliates

nce-based Practice Center, 2016, for the Agency for Healthcare Research and Quality, (U.S. Department of Health and Human Services).

MEB-001 – Promising Phase 1 trial results

- Sleep Signal Analysis of Depression Burden (SAMDE) Study Phase 1 clinical trial completed in July 2023
- Aim of SAMDE Phase 1 trial was to detect the likelihood cMDE in individuals referred to sleep clinics for polysomnography (PSG) assessment using TRI's innovative AI-backed algorithm
- Results taken from 313 subjects across 12 sleep centres in five US states Findings highlighted a robust bidirectional relationship between mental illness and sleep

Phase 1 results highlight:

The ability for the test to correctly identify patients with the disease

72%

Sensitivity

The ability of the test to correctly identify patients without the disease

Specificity

The ratio of true negatives compared

to all those who had negative test results

Preliminary SAMDE Phase 1 trial data demonstrated a 7 out of 10 success rate identifying cMDE

Current screening accuracy ranges from 21% to 76% with a pooled average of 46%*





91%

Negative predictive value

Phase 2 SAMDE trial and interim results



 Phase 2 trial aims to detect likelihood of a cMDE using Clinician Reporting Outcomes (CRO) assessment in individuals referred to a sleep clinical for PSG assessment using TRI's algorithm

Phase 2 to test up to 400 participants from 15 US sleep centres – expected to be completed shortly (dependent on enrolments)

Results to be used for final algorithm development, which includes determining overall accuracy and algorithm performance

317 of 400 patients recruited with completion expected in coming weeks

When MEB-001 was tested on the first 140 patients from Phase 2, it showed:



86%

75%

Sensitivity

The ability for the test to correctly identify patients with the disease Specificity

The ability of the test to correctly identify patients without the disease

95%

Negative predictive value

The ratio of true negatives compared to all those who had negative test results

Commercial model and go to market strategy

Potential for rapid adoption of MEB-001 through strategic partnerships with US sleep labs

Commercial model

Currently, there are ~980,000 sleep tests done in the US per annum

- MEB-001 is designed to integrate into all existing sleep lab software and workflow systems
- Highly scalable SaaS business model No upfront cost, no additional capex required and seamless integration into current sleep lab technology
- Additional testing capabilities expected to significantly increase testing rates and drive additional revenue for sleep clinics
- Sleep clinic customers have the potential to increase their service offering following potential CMDE diagnosis via MEB-001, unlocking additional sales

- Leverage existing partnerships with sleep research centres to convert early adopters through trial partnerships

Go to market strategy

- Pursue validation of SAMDE clinical pathway via publication of research results in peer-reviewed scientific journals
- Expand advisory panel through direct engagement with leading experts in the fields of sleep research and mental health
- Targeted industry awareness campaigns through effective marketing materials and presentations at select conferences, including the AASM (American Academy of Sleep Medicine) and the World Sleep Congress



Multiple near-term value catalysts



Finalisation of comprehensive Phase 2 SAMDE study to validate data – study which has over 300 patients enrolled to-date and is advancing in accordance with its stated completion timeline (June quarter 2024).



F

Ongoing dialogue with the US Food & Drug Administration (FDA) following successful pre-submission meeting in February 2024, which formally established a pathway to US regulatory clearance for MEB-001 through the De Novo classification for novel medical devices.

Discussions underway with several third-party providers, including leading universities and government research agencies, for the commercial deployment of Stager technology as a complement to existing sleep research and analysis practices.

Ongoing training and refinement of the MEB-001 algorithm to further de-risk the regulatory process as TRI follows its stated strategy to pursue FDA clearance through the De Novo pathway.

Targeted strategies for direct engagement with medical industry groups and representative bodies for US GPs, to educate sector professionals who currently administer depression screening tools on the attributes of MEB-001 in line with ongoing clinical milestones

Contact

TrivarX Limited (ASX: TRI)

E: <u>Investors@trivarx.com</u>

A: 647 Beaufort Street, Mt Lawley, WA 6050

Kai Sun – Chief Operating Officer:

T: +61 433 549 602

E: Kai.sun@trivarx.com

Henry Jordan – Six Degrees Investor Relations

T: +61 431 271 538

E: <u>Henry.Jordan@sdir.com.au</u>



Appendix 1: Intellectual Property and patents

Four patents granted and currently active



2

US Pat. No. 10,638,965 - Issued 05 May 2020. Method and system for monitoring stress conditions.

US Pat. No. 10,039,485 - Issued 07 Aug 2018. Method and system for assessing mental state.

US Pat. No. 10,912,508 - Issued 09 Feb 2021.

Method and system for assessing mental state

4

US Pat. No. 9,861,308 - Issued 09 Jan 2018. Method and system for monitoring stress conditions.

Appendix 2: Clinical research and technology



Supervised Artificial Intelligence

Data has been taken from 400+ subjects to date:

- Prospective data collection remains ongoing
- Combining EEG and ECG enables the technology to map the connectivity between brain and heart activity throughout sleep stages
- TRI has identified novel sleep biomarkers that map a person's mood disorder

Clinical Study	SLEEP	SADB	SAMDE PI	SAMDE PII	Clinical Validation	
Status	Complete	Complete	Complete	Underway	Planned	
Software Module(s)	SEEG SHRV	SEEG SHRV	SEEG SHRV DMI	SEEG SHRV DMI	SEEG SHRV DMI	
Location	USA	USA	USA	USA	USA	
Study Size	40	329	313	Up to 400	TBD	
Study Dates	2019	2019	2021	2023	2024 (Planned Study Start)	
Subjective Data	None	BDI PHQ-9	MINI (PRO) PHQ-9	MINI (CRO) PHQ-9	MINI (CRO) PHQ-9	
Value Delivered	Internal POC for Supervised Al	Early AI performance data vs. PRO	Enhanced PRO w/reduced noise and broadened symptoms	Use of MINI (CRO) as proposed ground truth	US FDA clearance	
Objective Data	EEG ECG	EEG ECG	EEG ECD Socio-demographics	EEG ECG Socio- demographics	EEG ECG Socio- demographics Risk Factors	
Hardware	In-Lab Polysomnography					
Focus	Autonomic Function	De	Depressive Symptoms +Disorder Risk			